Drug profile · INN
phenazopyridine hydrochloride
AZO GANTANOL
phenazopyridine hydrochloride (AZO GANTANOL) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Drug details — phenazopyridine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
phenazopyridine hydrochloride (AZO GANTANOL) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is phenazopyridine hydrochloride?
phenazopyridine hydrochloride (AZO GANTANOL) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for phenazopyridine hydrochloride?
AZO GANTANOL is a marketed brand name for phenazopyridine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of phenazopyridine hydrochloride?
phenazopyridine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.